We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $60.03, marking a -0.94% move from the previous day. This change lagged the S&P 500's 0.21% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Prior to today's trading, shares of the heart monitoring device maker had lost 9.04% over the past month. This has lagged the Medical sector's loss of 0.07% and the S&P 500's gain of 2.57% in that time.
Investors will be hoping for strength from BEAT as it approaches its next earnings release. In that report, analysts expect BEAT to post earnings of $0.43 per share. This would mark year-over-year growth of 10.26%. Our most recent consensus estimate is calling for quarterly revenue of $104.29 million, up 10.36% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $1.94 per share and revenue of $439.74 million, which would represent changes of 0% and +10.08%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT currently has a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BEAT has a Forward P/E ratio of 31.2 right now. Its industry sports an average Forward P/E of 22.49, so we one might conclude that BEAT is trading at a premium comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $60.03, marking a -0.94% move from the previous day. This change lagged the S&P 500's 0.21% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Prior to today's trading, shares of the heart monitoring device maker had lost 9.04% over the past month. This has lagged the Medical sector's loss of 0.07% and the S&P 500's gain of 2.57% in that time.
Investors will be hoping for strength from BEAT as it approaches its next earnings release. In that report, analysts expect BEAT to post earnings of $0.43 per share. This would mark year-over-year growth of 10.26%. Our most recent consensus estimate is calling for quarterly revenue of $104.29 million, up 10.36% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $1.94 per share and revenue of $439.74 million, which would represent changes of 0% and +10.08%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT currently has a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that BEAT has a Forward P/E ratio of 31.2 right now. Its industry sports an average Forward P/E of 22.49, so we one might conclude that BEAT is trading at a premium comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.